NMR LipoProfile (Nuclear Magnetic Resonance Lipoprotein Particle Analysis)
The NMR LipoProfile uses nuclear magnetic resonance spectroscopy to count and size lipoprotein particles directly, reporting LDL particle number, subfractions including small dense LDL, and a lipoprotein insulin resistance score. LDL particle number tracks cardiovascular risk more closely than LDL cholesterol where the two are discordant, though apolipoprotein B conveys substantially equivalent…
3
Biomarkers
Blood (plasma)
Sample
3–7 business days
Turnaround
No — LDL particle number is reliable on a non-fasting specimen, though a fasting sample improves comparability of the triglyceride-rich particle measures, subfraction distribution, and the LP-IR score
Fasting
What is the NMR LipoProfile test?
The NMR LipoProfile uses nuclear magnetic resonance spectroscopy to count and size lipoprotein particles directly from a single scan, reporting LDL particle number, lipoprotein subfractions including small dense LDL, HDL and VLDL particle measures, and a composite lipoprotein insulin resistance score. It is ordered to refine cardiovascular risk assessment beyond a conventional lipid panel, particularly in patients whose cholesterol values appear reassuring but whose metabolic profile suggests continuing risk. The rationale for measuring particle number is sound and worth stating clearly. Atherosclerosis is driven by apoB-containing particles entering and being retained in the arterial wall, and each particle carries that risk irrespective of how much cholesterol it contains. LDL cholesterol reports cholesterol content, not particle count, and the two diverge whenever particles are cholesterol-depleted — characteristically in insulin resistance, metabolic syndrome, type 2 diabetes, and hypertriglyceridaemia. In these patients a person may reach an LDL-C target while retaining a high particle number and residual risk, and LDL-P identifies that discordance. The NMR method itself is well established, is performed on a single scan without chemical separation, and can be run on a non-fasting specimen. The honest question is not whether particle number matters — it does — but whether NMR is the right way to measure it. Apolipoprotein B provides substantially the same information, since each atherogenic particle carries exactly one apoB molecule, and ApoB and LDL-P correlate very closely. ApoB is standardised against international reference material, is widely available on routine chemistry platforms, is less expensive, and is the particle measure that appears in major guidelines, where LDL-P largely does not. For the core clinical question of atherogenic particle burden, ApoB is therefore the more practical route to the same answer. What NMR adds beyond ApoB is the ancillary output: subfraction detail and the LP-IR score. These are the genuine differentiators, and both warrant measured expectations. Small dense LDL is a real and reproducible phenotype, but it correlates strongly with total particle number and with triglyceride and insulin-resistant states, and the evidence that it predicts risk independently once LDL-P or ApoB is accounted for is inconsistent — so subfraction data are better read as describing metabolic phenotype than as independently actionable. The LP-IR score is validated against clamp-derived insulin sensitivity and may flag insulin resistance before glucose and HbA1c become abnormal, but it is not a diagnostic criterion and does not displace established glycaemic testing. NMR is therefore best used where a practitioner specifically wants the metabolic phenotyping alongside particle number, rather than as a routine substitute for a lipid panel with ApoB.
What does the NMR LipoProfile test measure?
Nuclear magnetic resonance spectroscopy exploits the fact that lipoprotein particles of different size emit distinct magnetic signals from the methyl groups of their lipid constituents. The amplitude of each signal is proportional to the number of particles emitting it, allowing particle concentrations to be derived directly from a single scan without chemical separation. LDL particle number counts the circulating low-density lipoprotein particles themselves rather than the cholesterol they carry, and the two diverge whenever particles are cholesterol-depleted.
LDL particle number is the principal output of this assay and the measure with the strongest supporting evidence. Atherogenesis is driven by the number of apoB-containing particles entering and being retained in the arterial wall rather than by their cholesterol content, so LDL-P is mechanistically the more relevant exposure. Where LDL-P and LDL-C are discordant — common in insulin resistance, metabolic syndrome, type 2 diabetes, and hypertriglyceridaemia — LDL-P tracks cardiovascular risk more closely, and this discordance is the principal reason to order the test. Apolipoprotein B conveys substantially the same information, is standardised and more widely available, and appears in guidelines where LDL-P largely does not.
The same NMR scan resolves lipoprotein particles by size, yielding LDL particle size, small dense LDL particle concentration, HDL particle number, and VLDL particle number and size. Small dense LDL particles have reduced affinity for the LDL receptor, longer residence time in circulation, and greater susceptibility to oxidation, which underlies the hypothesis that they are disproportionately atherogenic. This phenotype is characteristically associated with insulin resistance and hypertriglyceridaemia.
Subfraction analysis is a genuine differentiator of NMR relative to simpler particle measures, and the small dense LDL phenotype is a recognised and reproducible metabolic pattern. Its independent clinical utility is more limited than often presented: small dense LDL correlates strongly with total LDL particle number and with triglyceride and insulin-resistant states, and the evidence that it adds risk prediction beyond LDL-P or apolipoprotein B once those are accounted for is inconsistent. Subfraction data are best regarded as descriptive of metabolic phenotype rather than as independently actionable, and treatment decisions should rest on particle number and global risk.
The lipoprotein insulin resistance score is a composite index computed from six lipoprotein subclass measures — large VLDL, large HDL, small LDL, and the average sizes of VLDL, LDL, and HDL particles — that shift characteristically with insulin resistance. It exploits the fact that insulin resistance produces a recognisable lipoprotein signature before conventional glycaemic markers become abnormal, and has been validated against the hyperinsulinaemic euglycaemic clamp.
The LP-IR score is a validated marker of insulin resistance and correlates reasonably with clamp-derived measures and with incident type 2 diabetes in cohort studies. Its practical value is that it is derived from the same scan at no additional collection burden, and it may identify insulin resistance in patients whose fasting glucose and HbA1c remain normal. It does not replace established assessment: fasting glucose, HbA1c, and where indicated an oral glucose tolerance test remain the diagnostic tests for dysglycaemia, and LP-IR is not a diagnostic criterion for insulin resistance, prediabetes, or diabetes.
Why is the NMR LipoProfile test ordered?
- Refinement of cardiovascular risk in patients with insulin resistance, metabolic syndrome, type 2 diabetes, or hypertriglyceridaemia, where LDL particle number and LDL cholesterol commonly diverge
- Assessment of residual risk in statin-treated patients who have reached an LDL cholesterol target but remain clinically at risk
- Evaluation of patients whose lipid panel appears reassuring but whose clinical picture, family history, or imaging suggests continuing atherosclerotic risk
- Situations where a practitioner specifically wants lipoprotein subfraction phenotyping and the insulin resistance score alongside particle number, rather than particle number alone
- Metabolic assessment where the LP-IR score may identify insulin resistance before fasting glucose and HbA1c become abnormal, used alongside rather than instead of those tests
- Monitoring of response to lipid-lowering or metabolic therapy where particle number is the preferred measure of response, using the same method throughout
- Patients in whom calculated LDL cholesterol is unreliable — markedly elevated triglycerides, non-fasting collection, or very low LDL cholesterol — noting that apolipoprotein B addresses this more simply
Sample collection and turnaround
Sample type
Blood (plasma)
Fasting required
No — LDL particle number is reliable on a non-fasting specimen, though a fasting sample improves comparability of the triglyceride-rich particle measures, subfraction distribution, and the LP-IR score
Collection method
Venipuncture at patient service centre
Turnaround
3–7 business days
Collection notes
A fasting morning specimen is preferred where the subfraction profile and LP-IR score are of interest, since postprandial changes affect triglyceride-rich particles. Defer testing during acute illness or for several weeks after a myocardial infarction. Document lipid-lowering therapy and any recent dose change, pregnancy status, thyroid status, and secondary causes of dyslipidaemia. Use the same method and laboratory for serial monitoring, since NMR values are not interchangeable with other particle measures.
Specimen requirements
Whole blood collected into the tube type specified by Access Medical Laboratories for NMR analysis, with plasma separated per protocol. Follow Access Medical Laboratories transport and storage guidelines.
What can affect NMR LipoProfile results?
The acute-phase response alters lipoprotein metabolism and particle distribution, so measurement should be deferred for several weeks after an acute event or during significant intercurrent illness.
Statins, ezetimibe, and PCSK9 inhibitors reduce particle number, though the reduction in LDL-P is frequently smaller than the reduction in LDL cholesterol — which is precisely why residual particle number can persist despite an at-target LDL-C, and why on-treatment particle measurement is informative.
Postprandial changes alter VLDL and triglyceride-rich particle measures and can affect subfraction distribution and the LP-IR score, though LDL particle number is relatively robust. A fasting specimen improves comparability for the metabolic outputs.
These secondary causes of dyslipidaemia raise atherogenic particle concentrations and should be identified and treated before an elevated particle number is attributed to primary dyslipidaemia.
Lipoprotein concentrations and particle distribution change substantially through gestation, so results are not interpreted against standard risk thresholds in pregnancy.
NMR-derived particle concentrations and subfraction values are specific to the NMR algorithm and are not interchangeable with those from other particle-sizing technologies such as gradient gel electrophoresis or ion mobility, nor directly with apolipoprotein B. Serial monitoring must use the same method and laboratory.
What do NMR LipoProfile results mean?
Elevated
An elevated LDL particle number indicates a high circulating atherogenic particle burden and identifies increased risk, including in patients whose LDL cholesterol appears acceptable — this discordance is the principal clinical yield of the test. Secondary causes including untreated hypothyroidism, nephrotic syndrome, and cholestatic liver disease should be excluded. An elevated small dense LDL concentration or LP-IR score describes an insulin-resistant metabolic phenotype and should prompt assessment of glycaemic status with fasting glucose and HbA1c, alongside attention to weight, diet, and physical activity, rather than being treated as an independent target.
Normal
A normal particle number is reassuring but is interpreted alongside global cardiovascular risk, lipoprotein(a), and the remainder of the lipid profile. It does not exclude atherosclerosis and does not establish low risk in a patient with other major risk factors. A normal LP-IR score does not exclude insulin resistance or prediabetes, for which established glycaemic testing remains the appropriate assessment.
Reduced
A low LDL particle number reflects a low atherogenic particle burden and is generally favourable, and is the expected response to effective lipid-lowering therapy. Very low values may reflect intensive combination therapy, malnutrition, hyperthyroidism, severe hepatic disease, or a genetic hypobetalipoproteinaemia. A low LP-IR score indicates a lipoprotein profile consistent with preserved insulin sensitivity but does not exclude dysglycaemia, which requires glucose and HbA1c assessment.
Note: The particle number rationale is sound, but apolipoprotein B conveys substantially equivalent information, is standardised, more widely available, less expensive, and better supported in guidelines, so NMR's incremental value for the core question of atherogenic particle burden is modest. Subfraction data correlate strongly with particle number and insulin-resistant states and add inconsistent independent predictive value, so they describe phenotype rather than providing separate treatment targets. The LP-IR score is validated for risk stratification but is not a diagnostic criterion and does not replace glucose and HbA1c. Values are method-specific and not comparable with other particle-sizing technologies or directly with ApoB, and serial monitoring requires the same method.
Frequently asked questions
It uses nuclear magnetic resonance to count and size lipoprotein particles directly from a single scan, reporting LDL particle number, subfractions including small dense LDL, HDL and VLDL measures, and a lipoprotein insulin resistance score.
How to access the NMR LipoProfile test
The NMR LipoProfile reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: July 16, 2026
Last reviewed: July 16, 2026
- Otvos JD, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. (2011)
- Cromwell WC, et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study. J Clin Lipidol. (2007)
- Sniderman AD, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. (2019)
- Shalaurova I, et al. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab Syndr Relat Disord. (2014)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
cardiovascular
Apo-B
The Apolipoprotein B (Apo-B) test counts the total number of atherogenic lipoprotein particles, since each LDL, VLDL, IDL, and lipoprotein(a) particle carries one apolipoprotein B. It is a strong cardiovascular risk marker, in many analyses superior to LDL cholesterol because it captures particle number rather than cholesterol content, and is especially informative where LDL cholesterol…
cardiovascular
HDL-C
The HDL cholesterol test measures the cholesterol carried within high-density lipoprotein particles, a core component of the lipid profile and cardiovascular risk assessment. Low HDL-C is an independent risk marker, but HDL-C reflects cholesterol concentration rather than HDL function and is a risk marker, not a validated treatment target;
cardiovascular
Lipid Panel
The standard lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, and derives non-HDL cholesterol, providing the core assessment of cardiovascular lipid risk. LDL-C is the principal treatment target and non-HDL-C an increasingly used secondary measure.